Tenaya Therapeutics, Inc. (TNYA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Tenaya Therapeutics reported revenue of $0. Net income was -$90.6M, or -$0.59 per diluted share. Operating activities generated -$68.3M of cash, leaving -$68.9M of free cash flow. At fiscal year end, Tenaya Therapeutics held $146.9M in total assets against $23.7M in total liabilities, including $100.5M of cash and equivalents.
Open the full interactive Tenaya Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Tenaya Therapeutics Key Stats
| Share Price | $0.52 |
|---|---|
| Market Cap | $113.4M |
| 52-Week Range | $0.52 – $2.00 |
| Shares Outstanding | 217.6 million (basic, 2026 Q2) |
Tenaya Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$72.8M | -$125.6M | -$131.2M | -$115.9M | -$93.3M |
| Pre-Tax Income | -$72.7M | -$123.7M | -$124.1M | -$111.1M | -$90.6M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$72.7M | -$123.7M | -$124.1M | -$111.1M | -$90.6M |
| Diluted EPS | -$4.10 | -$2.76 | -$1.68 | -$1.31 | -$0.59 |
Tenaya Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $225,000 | $1.1M |
| Net Income | -$20.3M | -$20.2M | -$19.3M | -$43.4M |
| Diluted EPS | -$0.12 | -$0.13 | -$0.09 | -$0.20 |
Tenaya Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $38.1M | $95.3M | $45.7M | $4.3M | $100.5M |
| Current Assets | $255.4M | $193.8M | $111.6M | $67.4M | $105.6M |
| Total Assets | $314.2M | $278.9M | $170.5M | $119.9M | $146.9M |
| Current Liabilities | $21.8M | $24.2M | $22.7M | $16.0M | $15.4M |
| Total Liabilities | $35.7M | $35.6M | $31.1M | $27.1M | $23.7M |
| Shareholders' Equity | $278.5M | $243.4M | $139.4M | $92.9M | $123.3M |
Tenaya Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$60.8M | -$104.4M | -$102.1M | -$90.5M | -$68.3M |
| Cash From Investing | -$238.6M | $83.7M | $48.7M | $1.1M | $56.1M |
| Cash From Financing | $209.0M | $77.8M | $4.0M | $47.7M | $108.4M |
| Free Cash Flow | -$85.9M | -$125.1M | -$103.3M | -$91.5M | -$68.9M |
Figures from Tenaya Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Tenaya Therapeutics financials page for every line item.
Tenaya Therapeutics Company Profile
| Ticker | TNYA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001858848 |
Frequently Asked Questions
What was Tenaya Therapeutics' revenue in fiscal 2025?
Tenaya Therapeutics (TNYA) reported revenue of $0 for fiscal 2025.
What is Tenaya Therapeutics' annual revenue history?
Tenaya Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Tenaya Therapeutics' net income in fiscal 2025?
Tenaya Therapeutics reported net income of -$90.6M for fiscal 2025.
What was Tenaya Therapeutics' earnings per share (EPS) in fiscal 2025?
Tenaya Therapeutics' diluted EPS was -$0.59 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Tenaya Therapeutics generate in fiscal 2025?
Tenaya Therapeutics generated -$68.9M of free cash flow in fiscal 2025.
What was Tenaya Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Tenaya Therapeutics reported revenue of $1.1M.
How many shares of Tenaya Therapeutics are outstanding?
Tenaya Therapeutics reported a weighted average of 217.6 million basic shares outstanding in 2026 Q2.
What is Tenaya Therapeutics' market cap?
Based on its latest closing price, Tenaya Therapeutics (TNYA) has a market capitalization of about $113.4M.
When does Tenaya Therapeutics' fiscal year end?
Tenaya Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Tenaya Therapeutics headquartered?
Tenaya Therapeutics lists its business address in South San Francisco, California in its SEC filings.
Tenaya Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →